ClinicalTrialsFinder
Not Yet RecruitingPhase 3ACTRN12605000397617

Towards better assessment and treatment of exercise induced wheeze

Comprehensive assessment of patients with exercise induced wheeze using pulmonary function testing, bronchial challenge testing (methacholine and Mannitol) and exhaled nitric oxide. A comparison of either inhaled steroids or a cross-over study of cromoglycate, montelukast and formoterol

Sponsor

University of Otago

Enrollment

60 participants

Start Date

Nov 1, 2005

Study Type

Interventional

Conditions

Exercise induced wheezeAsthma

Summary

Exercise induced symptoms are common especially in patients with asthma. There are several possible treatments for exercise induced wheeze. This study aims to provide further evidence to help GPs decide on which treatment is best for an individual patient

Eligibility

Sex: Both males and femalesMin Age: 12 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Towards better assessment and treatment of exercise induced wheeze. It may be open to adults aged 12 and older who exercise induced wheeze, cough or dyspnoea are the primary symptoms. People with current or recent ex-smokers, patients taking oral or inhaled steroids in the previous 6 weeks may not be eligible. Participation typically involves regular medical visits, tests, and following the study's treatment plan.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Following comprehensive assessment, patients with exercise induced symptoms will be divided into two groups according to their baseline exhaled nitric oxide levels (FeNO). Those with a high FeNO (>35p

Following comprehensive assessment, patients with exercise induced symptoms will be divided into two groups according to their baseline exhaled nitric oxide levels (FeNO). Those with a high FeNO (>35ppb) will receive inhaled fluticasone for 6 weeks.

Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000397617

Related Trials

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

NCT06307665135 locations

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

NCT073996659 locations

Personalized Environment and Genes Study

NCT003412371 location

PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults

NCT069811693 locations

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589143 locations